On March 20, 2024 at 9 am PST, Boyds will host a webinar designed to provide attendees with a plan of action that can help to de-risk your Investigational New Drug (IND) application and expedite the path to gain study clearance.
Dr. Nick Meyers, Vice President of Product Development and Katy Rudnick, Vice President and Head of US Regulatory Affairs, will take you through the IND preparation process explaining de-risking activities that save time and cost while promoting quick advancement of your product into the clinic. Thoroughly planning the strategy, timing, content, and delivery of the IND is critical to avoid unnecessary delays to your development program.
To secure your free place on the webinar, register using the link: Webinar Registration – Zoom.
